Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Children's Hospital of Philadelphia
With
C.S. Mott Children's Hospital
Children's Healthcare of Atlanta
Ann & Robert H Lurie Children's Hospital of Chicago
Children's Medical Center Dallas
Children's Hospital of Michigan
Baylor College of Medicine
University of Mississippi Medical Center
Arkansas Children's Hospital Research Institute
Ochsner Health System
Lucile Packard Children's Hospital
Primary Children's Hospital
Rady Children's Hospital, San Diego
Seattle Children's Hospital
Patient-Centered Outcomes Research Institute
Children's Hospital Colorado
Alfred I. duPont Hospital for Children
Dana-Farber Cancer Institute
This is a bidirectional observational cohort study.
Participants will be patients less that 19 years of age at diagnosis receiving or having received chemotherapy for AML from seventeen participating pediatric hospitals across the United States. There is no study intervention; this is a medical record abstraction study only. Investigators will abstract subjects medical record data over the study period in order to study clinical outcomes including the occurrence of bacteremia and time to the start of the next course in the chemotherapy regimen, in relation to neutropenia management strategy.
Age
0–19
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Males or females of age less than 19 at diagnosis.
2. Receipt or planned receipt of AML chemotherapy between January 1, 2012 and December 31, 2019.
You may not be if
1. Patients being treated for relapsed AML
2. Patients with Acute Promyelocytic Leukemia (APML)
